Creative Planning Purchases Shares of 20,328 Standard BioTools Inc. (NASDAQ:LAB)

Creative Planning purchased a new stake in Standard BioTools Inc. (NASDAQ:LAB) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,328 shares of the company’s stock, valued at approximately $39,000.

Other large investors also recently made changes to their positions in the company. Freestone Capital Holdings LLC bought a new position in shares of Standard BioTools in the first quarter valued at approximately $31,000. Shell Asset Management Co. bought a new position in shares of Standard BioTools in the first quarter valued at approximately $39,000. Peak Asset Management LLC bought a new position in shares of Standard BioTools in the first quarter valued at approximately $46,000. BNP Paribas Financial Markets boosted its holdings in shares of Standard BioTools by 1,775,900.0% in the first quarter. BNP Paribas Financial Markets now owns 17,760 shares of the company’s stock valued at $48,000 after acquiring an additional 17,759 shares in the last quarter. Finally, Xponance Inc. bought a new stake in Standard BioTools during the second quarter worth approximately $34,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen reduced their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Insider Transactions at Standard BioTools

In related news, Director Casdin Partners Master Fund, L acquired 500,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were bought at an average price of $1.90 per share, for a total transaction of $950,000.00. Following the acquisition, the director now owns 53,025,821 shares in the company, valued at $100,749,059.90. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have purchased 1,192,100 shares of company stock worth $2,357,173. 53.10% of the stock is currently owned by company insiders.

Standard BioTools Price Performance

Shares of LAB opened at $1.84 on Thursday. The company has a market capitalization of $684.96 million, a PE ratio of -2.59 and a beta of 1.57. Standard BioTools Inc. has a one year low of $1.21 and a one year high of $3.04. The company’s fifty day moving average price is $1.93 and its 200 day moving average price is $2.07.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.